• Publications
  • Influence
The Banff 97 working classification of renal allograft pathology.
TLDR
Major changes include the following: rejection with vasculitis is separated from tubulointerstitial rejection; severe rejection requires transmural changes in arteries; "borderline" rejection can only be interpreted in a clinical context; antibody-mediated rejection is further defined, and lesion scoring focuses on most severely involved structures.
Antibody‐Mediated Rejection Criteria – an Addition to the Banff ′97 Classification of Renal Allograft Rejection
TLDR
This article presents international consensus criteria for and classification of AbAR developed based on discussions held at the Sixth Banff Conference on Allograft Pathology in 2001, to be revisited as additional data accumulate in this important area of renal transplantation.
Banff '05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (‘CAN’)
TLDR
The 8th Banff Conference on Allograft Pathology was held in Edmonton, Canada, 15–21 July 2005, and major outcomes included the elimination of the non‐specific term ‘chronic allograft nephropathy’ (CAN) and the recognition of the entity of chronic antibody‐mediated rejection.
Reduced exposure to calcineurin inhibitors in renal transplantation.
TLDR
A regimen of daclizumab, mycophenolate mofetil, and corticosteroids in combination with low-dose tacrolimus may be advantageous for renal function, allograft survival, and acute rejection rates, as compared with regimens containing dacluzumab induction plus either low- doses of cyclosporine or low- dose sirolimus or with standard-dose cyclosporaine without induction.
Banff ’09 Meeting Report: Antibody Mediated Graft Deterioration and Implementation of Banff Working Groups
TLDR
The willingness of the Banff process to adapt continuously in response to new research and improve potential weaknesses, led to the implementation of six working groups on the following areas: isolated v‐lesion, fibrosis scoring, glomerular lesions, molecular pathology, polyomavirus nephropathy and quality assurance.
Immunosuppressive drugs for kidney transplantation.
  • P. Halloran
  • Medicine
    The New England journal of medicine
  • 23 December 2004
TLDR
This review considers the use of immunosuppressive drugs in organ transplantation, focusing on renal transplantation.
International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology.
TLDR
A schema for international standardization of nomenclature and criteria for the histologic diagnosis of renal allograft rejection was developed in Banff, Canada on August 2-4, 1991 and validated by the circulation of sets of slides for scoring by participant pathologists.
Improving gene set analysis of microarray data by SAM-GS
TLDR
It is concluded that GSEA has important limitations as a gene-set analysis approach for microarray experiments for identifying biological pathways associated with a binary phenotype and an alternative statistically-sound method is proposed, SAM-GS.
Endothelial Gene Expression in Kidney Transplants with Alloantibody Indicates Antibody‐Mediated Damage Despite Lack of C4d Staining
TLDR
High renal endothelial transcript expression in patients with alloantibody is indicator of active antibody‐mediated allograft damage and poor graft outcome and was validated in independent set of 82 kidneys.
Rethinking chronic allograft nephropathy: the concept of accelerated senescence.
TLDR
A model in which the cumulative burden of injury and age exhausts the ability of key cells in epithelium or endothelium to repair and remodel to maintain tissue integrity is proposed, calling this exhaustion “senescence” to emphasize the importance of donor aging and the overlap of the pathologic lesions with age-related changes.
...
1
2
3
4
5
...